e-learning
resources
Vienna 2009
Tuesday, 15.09.2009
Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inferon administration to patients with chronic obstructive pulmonary disease
S. Farkhutdinov, U. Farkhutdinov (Ufa, Russian Federation)
Source:
Annual Congress 2009 - Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation
Session:
Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation
Session type:
E-Communication Session
Number:
3102
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Farkhutdinov, U. Farkhutdinov (Ufa, Russian Federation). Inferon administration to patients with chronic obstructive pulmonary disease. Eur Respir J 2009; 34: Suppl. 53, 3102
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Inferon efficacy in the treatment of chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD
Year: 2008
The results of inferon administration in the treatment of chronic obstructive pulmonary disease
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012
IL-8 in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 364s
Year: 2001
Rhinovirus-infection in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 591s
Year: 2002
Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients
Source: Eur Respir J 2003; 21: 58-67
Year: 2003
Systemic effects of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 347-360
Year: 2003
Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Systemic inflammation and increased arterial stiffness in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2006 - COPD and inflammation
Year: 2006
Systemic inflammation in chronic obstructive pulmonary disease in patients with pulmonary hypertension
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Mortality in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 210s
Year: 2001
High interleukin-33 is associated with acute exacerbation in patients with chronic obstructive pulmonary disease
Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Year: 2020
Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Systemic inflammation in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: 5S-13S
Year: 2003
Pulmonary rehabilitation of patients with acute exacerbation of chronic obstructive pulmonary disease
Source: Annual Congress 2010 - Exacerbations and COPD and rehabilitation
Year: 2010
Fenspiride efficacy in the treatment of chronic obstructive pulmonary disease
Source: International Congress 2017 – Novel mechanisms and treatments for COPD
Year: 2017
Enalapril in the management of patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 241s
Year: 2003
Periodontitis and chronic obstructive pulmonary disease
Source: Annual Congress 2006 - COPD and inflammation
Year: 2006
Prevalence of bronchiectasis in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 60s
Year: 2006
Bronchodilators in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=266
Year: 2006
Chronic pain in patients with chronic obstructive pulmonary disease
Source: International Congress 2018 – Patient-reported outcomes and scores in COPD
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept